Ventracor growth sends annual loss up 68%
18 August, 2005 by Ruth BeranArtificial heart company Ventracor (ASX:VCR) has posted a net loss of $AUD26.6 million for 2004-05, up 68 per cent from $15.9 million in the previous financial year.
Antisense CEO takes good with bad in end-of-year figures
18 August, 2005 by Helen SchullerMelbourne's Antisense Therapeutics (ASX:ANP) has reported a full-year after-tax loss of AUD$6.2 million, up from $4.6 million from last year, in results described by CEO Mark Diamond as "good news tinged with less than positive news".
Stirling's ST810 shows beneficial effects in broiler chickens
16 August, 2005 by Ruth BeranStirling Products' (ASX:STI) second study into the effects of its lead beta agonist growth promotion product ST810 in broiler chickens has shown positive preliminary results, according to the company.
Mesoblast appoints executive chairman
16 August, 2005 by Helen SchullerAdult stem cell company Mesoblast (ASX:MSB) has appointed Michael Spooner as full-time executive chairman until June 30 next year.
CollTech raises $1.1m
16 August, 2005 by Helen SchullerWestern Australian collagen purification company CollTech (ASX:CAU) has raised AUD$1.1 million by way of a private placement to institutional and professional investors.
Cochlear chalks up record revenues
16 August, 2005 by Helen SchullerCochlear (ASX:COH), the world's top maker of hearing implants, has turned around a poor performance from last year to record a net profit of AUD$54.52 million, up 48 per cent from last year.
Stoush over, Polartechnics to hunt for profit
16 August, 2005 by Ruth BeranVictor Skladnev won't talk about last Friday's extraordinary general meeting of Polartechnics (ASX:PLT) shareholders. Referring only to the "disruptions" -- in which erstwhile chairman Richard Opara tried and failed to replace Skladnev as CEO -- Skladnev is keen to put the past behind him and focus on driving profits into the company.
Psivida and Solbec granted US patents
16 August, 2005 by Ruth BeranPsivida has been granted its fifth US patent for the classification of porous silicon into monodispersed particles with a tight size distribution.
Paragon Equity acquires 10% of BresaGen
16 August, 2005 by Ruth BeranAdelaide-based venture and development capital firm Paragon Equity has invested more than $AUD850,000 to acquire a 10 per equity holding of Adelaide biopharma BresaGen (ASX:BGN).
Amrad confirms Nash in CEO role
15 August, 2005 by Helen SchullerAndrew Nash has been named CEO of Amrad Corporation (ASX:AML), three months after he stepped into the role following the resignation of Peter Smith in May.
NeuroDiscovery makes market debut
15 August, 2005 by Helen SchullerPerth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20.
German Relenza deal shows we're right: Biota
15 August, 2005 by Helen SchullerMelbourne-based biopharma Biota Holdings (ASX:BTA) has confirmed that the German government has ordered 1.7 million packs of its flu vaccine Relenza, but CEO Peter Molloy said he still believed that licensee GlaxoSmithKline was not doing enough to promote the drug, .
Phylogica and PharmAust sign partnering deal
15 August, 2005 by Ruth BeranPhylogica (ASX:PYC) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a collaborative partnership deal to develop peptide drugs.
Polartechnics EGM nixes Opara resolutions
15 August, 2005 by Ruth BeranAn extraordinary general meeting of Polartechnics (ASX:PLT) shareholders, requisitioned by the company's former interim chairman Richard Opara, has voted against each of the resolutions he put forward.
Psivida in talks to acquire US drug delivery company
15 August, 2005 by Ruth BeranTrading of shares in Perth-based nano-biotech company Psivida (ASX:PSD) resumed trading today, after the company revealed that it was in negotiations to acquire an as yet unnamed US based specialised drug delivery company.
